Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report

  • Mururul Aisyi Department of Pediatric Hematology Oncology, Indonesia National Cancer Center, Dharmais Cancer Hospital, Jakarta, Indonesia; Department of Research and Development, Indonesia National Cancer Center, Dharmais Cancer Hospital, Jakarta, Indonesia https://orcid.org/0000-0001-9754-5696
  • Ayu Hutami Syarif Department of Research and Development, Indonesia National Cancer Center, Dharmais Cancer Hospital, Jakarta, Indonesia
  • Nur Asih Department of Research and Development, Indonesia National Cancer Center, Dharmais Cancer Hospital, Jakarta, Indonesia
  • Agus Kosasih Department of Clinical Pathology, Indonesia National Cancer Center, Dharmais Cancer Hospital, Jakarta, Indonesia
Keywords: children, chronic myeloid leukemia, tyrosine kinase inhibitor
Abstract viewed: 952 times
PDF downloaded: 656 times
HTML downloaded: 66 times
EPUB downloaded: 248 times


Pediatric chronic myeloid leukemia (CML) is a hematopoietic malignancy, treated by tyrosine kinase inhibitor (TKI). Previously, imatinib resistance in CML was treated with nilotinib as a second line. However, in Indonesia, where the options of TKIs are limited, no case has been reported. We describe TKI-resistance of a pediatric CML case in Dharmais Cancer Hospital, Jakarta. A 17-year-old boy presented with loss of complete hematologic response after 4 years of imatinib treatment. Diagnosis of relapsed CML with blast crisis was confirmed, and nilotinib was given accordingly. He achieved hematological and optimal response after 2 weeks and 3 months of treatment, respectively. However, in the 12-month evaluation, he failed to achieve major molecular response and acquired the second resistance to TKI. Since imatinib resistance marks the poor prognosis, initial optimal response of nilotinib treatment remains inconclusive to predict the final outcome.


  1. Al-Jafar HA, Al-Mulla A, AlDallal S, Buhamad JH, Askar H. Successful nilotinib treatment in a child with chronic myeloid leukemia. Case Rep Oncol. 2015;8(1):122-7. https://doi.org/10.1159/000380905

  2. Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. Blood Rev. 2018;32(4):289-99. https://doi.org/10.1016/j.blre.2018.01.004

  3. Metibemu DS, Akinloye OA, Akamo AJ, Ojo DA, Okeowo OT, Omotuyi IO, et al. Exploring receptor tyrosine kinases-inhibitors in cancer treatments. Egypt J Med Hum Genet. 2019;20:35. https://doi.org/10.1186/s43042-019-0035-0

  4. Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, et al. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018;5;132(1):67-77. https://doi.org/10.1182/blood-2018-02-834895

  5. Bauer S, Buchanan S, Ryan I. Tyrosine kinase inhibitors for the treatment of chronic-phase chronic myeloid leukemia: long-term patient care and management. J Adv Pract Oncol. 2016;7(1):42-54. https://doi.org/10.6004/jadpro.2016.7.1.3

  6. Sacha T. Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis. 2014;6(1):e2014007. https://doi.org/10.4084/mjhid.2014.007

  7. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009;15(24):7519-27. https://doi.org/10.1158/1078-0432.CCR-09-1068

  8. Zaidi U, Kaleem B, Borhany M, Maqsood S, Fatima N, Sufaida G, et al. Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients. Cancer Manag Res. 2019;11:1493-502. https://doi.org/10.2147/CMAR.S181911

  9. Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2018;127(4):392-9. https://doi.org/10.1182/blood-2015-06-648667

  10. Kotiah S. Chronic myelogenous leukemia (CML) staging: phases of chronic myelogenous leukemia [Internet]. Medscape. 2019 [cited 2020 Mar 6]. p. 1. Available from: https://emedicine.medscape.com/article/2006731-overview.

  11. Hochhaus A, Druker BJ, Larson RA, O'Brien SG, Gathmann I, Guilhot F. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2007;110(11):25. https://doi.org/10.1182/blood.V110.11.25.25

  12. Millot F, Guilhot J, Baruchel A, Petit A, Bertrand Y, Mazingue F, et al. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood. 2014;124(15):2408-10. https://doi.org/10.1182/blood-2014-05-578567

  13. DeAngelo DJ, Attar EC. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leuk Lymphoma. 2010;51(3):363-75. https://doi.org/10.3109/10428190903518295

  14. Shin J, Koh Y, Yoon SH, Cho JY, Kim DY, Lee KH, et al. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea. Cancer Med. 2018;7(5):1814-23. https://doi.org/10.1002/cam4.1450

  15. Neelakantan P, Apperley JF. Therapy in Practice: nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines. Clin Pract. 2013;10(3):283-91. https://doi.org/10.2217/cpr.13.24

  16. Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, et al. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Br J Haematol. 2017;179(2):219-28. https://doi.org/10.1111/bjh.14829

  17. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17. https://doi.org/10.1056/NEJMoa062867

  18. FDA. FDA approves nilotinib for pediatric patients with newly diagnosed or resistant/intolerant Ph+ CML in chronic phase [Internet]. 2018 [cited 2020 Jan 5]. p. 1. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nilotinib-pediatric-patients-newly-diagnosed-or-resistantintolerant-ph-cml-chronic.

  19. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-84. https://doi.org/10.1182/blood-2013-05-501569

  20. Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, et al. Analysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities - analysis of 5 prospective clinical trials. Lancet Haematol. 2015;2(3):e118-28.

  21. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013;121(24):4867-74. https://doi.org/10.1182/blood-2013-03-490128

  22. Chansung K, Sirijerachai C, Lekhakula A, Viboonjuntra P, Niparuck P, Pauvilai T, et al. Nilotinib as second-line therapy in patients with chronic myeloid leukemia in chronic phase: Thailand experience. Blood. 2016;128(22):5448. https://doi.org/10.1182/blood.V128.22.5448.5448

  23. Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, et al. Frontline nilotinib inpatients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30(1):57-64. https://doi.org/10.1038/leu.2015.270

  24. Cannella L, Breccia M, Stefanizzi C, Napoleone L, Santopietro M, Alimena G. Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance. Leuk Lymphoma. 2009;50(5):848-50. https://doi.org/10.1080/10428190902829425

How to Cite
Aisyi M, Syarif AH, Asih N, Kosasih A. Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report. Med J Indones [Internet]. 2020Oct.16 [cited 2024May29];29(4):427-30. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/3765
Case Report/Series

Most read articles by the same author(s)